Incidence of Cancer in Patients with Irritable Bowl Syndrome.
IBS
cancer
functional disorder
gastrointestinal
tumor
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Dec 2021
16 Dec 2021
Historique:
received:
26
10
2021
revised:
08
12
2021
accepted:
13
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
(1) Background: Irritable bowel syndrome (IBS) represents one of the most common disorders of gut-brain interaction (DGBI). As recent data has suggested an increased cancer incidence for IBS patients, there is an ongoing debate whether IBS might be associated with a risk of cancer development. In the present study, we evaluated and compared incidence rates of different malignancies including gastrointestinal cancer in a large cohort of outpatients, with or without IBS, treated in general practices in Germany. (2) Methods: We matched a cohort of 21,731 IBS patients from the IQVIA Disease Analyzer database documented between 2000 and 2019 in 1284 general practices to a cohort of equal size without IBS. Incidence of cancer diagnoses were evaluated using Cox regression models during a 10-year follow-up period. (3) Results: In 11.9% of patients with IBS compared to 8.0% without IBS, cancer of any type was diagnosed within 10 years following the index date (
Identifiants
pubmed: 34945206
pii: jcm10245911
doi: 10.3390/jcm10245911
pmc: PMC8703949
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Arch Surg. 2004 Jul;139(7):760-5
pubmed: 15249410
Gastroenterology. 2011 Nov;141(5):1792-801
pubmed: 21820992
J Gastrointest Oncol. 2018 Aug;9(4):769-777
pubmed: 30151274
Breast Cancer Res Treat. 2019 Dec;178(3):493-496
pubmed: 31456069
Z Gastroenterol. 2011 Feb;49(2):237-93
pubmed: 21287438
Dtsch Arztebl Int. 2020 Oct 23;117(43):719-724
pubmed: 33559592
Oncol Rep. 2017 Sep;38(3):1393-1401
pubmed: 28713975
Am J Gastroenterol. 1985 Jan;80(1):42-6
pubmed: 3966453
Am J Clin Exp Immunol. 2017 Jun 15;6(4):60-65
pubmed: 28695058
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499223
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):133-146
pubmed: 28404070
Gut Pathog. 2011 Apr 26;3(1):6
pubmed: 21518462
J Exp Clin Cancer Res. 2011 Jan 20;30:11
pubmed: 21247505
Gastroenterol Clin North Am. 2005 Jun;34(2):235-45, vi-vii
pubmed: 15862932
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):345-354
pubmed: 29795140
Nature. 2021 Feb;590(7844):151-156
pubmed: 33442055
J Infect Dis. 2011 Apr 15;203(8):1101-9
pubmed: 21451000
Ann Epidemiol. 2015 Dec;25(12):924-8
pubmed: 26507852
Lancet. 2020 Nov 21;396(10263):1675-1688
pubmed: 33049223
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
Carcinogenesis. 2000 Apr;21(4):753-6
pubmed: 10753212
J Alzheimers Dis. 2021;79(1):37-46
pubmed: 33216039
Neurogastroenterol Motil. 2012 Jan;24(1):31-9
pubmed: 22070725
Scand J Gastroenterol. 2014 Sep;49(9):1068-75
pubmed: 24919810
Gut. 2014 Nov;63(11):1737-45
pubmed: 24310267
Gastroenterology. 2016 Feb 13;:
pubmed: 27144634
Gut. 2017 Jun;66(6):1075-1082
pubmed: 26818616
Ann Gastroenterol. 2018 Mar-Apr;31(2):171-187
pubmed: 29507464
Am J Clin Exp Immunol. 2021 Feb 15;10(1):23-29
pubmed: 33815960
Ann Gastroenterol Surg. 2017 Jun 07;1(2):99-104
pubmed: 29863142
Dig Liver Dis. 2009 Dec;41(12):844-9
pubmed: 19716778
Br J Cancer. 2011 Mar 29;104(7):1202-6
pubmed: 21343936
ACS Infect Dis. 2021 May 14;7(5):987-1009
pubmed: 33848139
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627